United Therapeutics Corporation - Common Stock (UTHR)
442.48
+5.15 (1.18%)
NASDAQ · Last Trade: Nov 5th, 12:20 PM EST
Detailed Quote
Previous Close
437.33
Open
432.53
Bid
442.47
Ask
444.22
Day's Range
432.53 - 444.98
52 Week Range
266.98 - 479.50
Volume
100,010
Market Cap
19.86B
PE Ratio (TTM)
16.75
EPS (TTM)
26.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
632,638
Chart
About United Therapeutics Corporation - Common Stock (UTHR)
United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies to treat chronic and life-threatening conditions, primarily in the fields of pulmonary hypertension and organ transplantation. Through its research efforts, the company aims to create and provide advanced medications that improve the quality of life for patients with severe health challenges. United Therapeutics is also engaged in initiatives to promote organ donation and transplantation, working towards enhancing the availability of organs for patients in need. Read More
United Therapeutics delivered a quarter that was well received by the market despite missing revenue expectations, as operational progress and clinical milestones took center stage. Management credited sales growth to continued expansion of the Tyvaso and Orenitram franchises, highlighting robust demand for Tyvaso DPI and minimal impact from new competition. CEO Martine Rothblatt emphasized that three Phase III trials reached full enrollment and that recently unblinded pulmonary fibrosis results represented “the best results for that condition ever reported by anyone, anywhere.” The quarter also benefited from commercial execution and new product features designed to enhance patient convenience.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences.
United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its EXPAND study of the UKidney™ in patients with end-stage renal disease (ESRD). The successful transplant operation was performed at NYU Langone Health.
United Therapeutics offers strong growth, high profitability, and a robust balance sheet, yet trades at a significant discount to the biotech industry. A top pick for affordable growth.
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per share was 2.3% above analysts’ consensus estimates.
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR)
jumped 11.7% in the afternoon session after the company reported record third-quarter financial results and announced positive outcomes from a key clinical study.
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100 points, both breaking new records, as investors brace for the Federal Reserve's
United Therapeutics posts record Q3 2025 revenue of $799.5M, driven by strong Tyvaso growth. The company beat EPS estimates but slightly missed on revenue.
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per share was 2.3% above analysts’ consensus estimates.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso® and Orenitram®. Total revenues in the third quarter of 2025 grew seven percent year-over-year to $799.5 million, compared to $748.9 million in the third quarter of 2024.
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market discussions about "dividend increases," the biotechnology firm has publicly stated it does not anticipate paying dividends in the immediate future. Instead, the company has
United Therapeutics (UTHR) aligns with Peter Lynch's investment strategy, showing strong earnings growth, a fair PEG ratio, and a debt-free balance sheet for long-term value.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
United Therapeutics (UTHR) is a strong value stock with a low P/E ratio, zero debt, high profitability, and solid growth, making it an undervalued biotech pick.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
